Allogene Therapeutics's total assets for Q4 2024 were $548.71M, a decrease of -6.86% from the previous quarter. ALLO total liabilities were $126.53M for the fiscal quarter, a 0.92% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.